Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 3/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28911294 | 0.88 | HTT (0.49) | ALDH1A1KMT2AMAPTMAPK1GAA | |
| SCHEMBL28541098 | 0.86 | HTT (0.43) | ALDH1A1KMT2AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL18922351 | 0.84 | HTT (0.42) | ALDH1A1KMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL1241438 | 0.82 | TSHR (0.40) | ALDH1A1KMT2AGAASMN1; SMN2ESR2 | |
| SCHEMBL21872488 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KMT2AMAPTMAPK1GAA | |
| SCHEMBL9572102 | 0.77 | HTT (0.47) | ALDH1A1KMT2AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL31621897 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL26557416 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KMT2AMAPTMAPK1MEN1 | |
| SCHEMBL28029980 | 0.75 | FYN (0.43) | ALDH1A1KMT2AMAPTMAPK1GAA | |
| SCHEMBL27383074 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574079-A | 2, 2-difluoro-N- (2-thioether cyclohexyl-1-alkene-1-base) acetamide and derivative and synthesis method thereof | 湖南工程学院 | 2021-03-30 | — | — | CN | claimed |
| WO-2025118590-A1 | HIGHLY-TRANSPARENT NYLON ELASTOMER POLYMER, PREPARATION METHOD, AND POLYMER THIN FILM | 浙江工业大学 | 2025-06-12 | — | — | WO | disclosed |
| CN-117487156-A | High-transparency nylon elastomer polymer, preparation method and polymer film | 浙江工业大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-112574079-A | 2, 2-difluoro-N- (2-thioether cyclohexyl-1-alkene-1-base) acetamide and derivative and synthesis method thereof | 湖南工程学院 | 2021-03-30 | — | — | CN | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | ALDH1A1 1721/4885KMT2A 944/4885MAPT 298/4885 |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | ALDH1A1 1721/4885KMT2A 944/4885MAPT 298/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | ALDH1A1 1721/4885KMT2A 944/4885MAPT 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.